Patrick D. Spangler - Jun 5, 2024 Form 4 Insider Report for OptimizeRx Corp (OPRX)

Role
Director
Signature
/s/ Marion Odence-Ford, by Power of Attorney
Stock symbol
OPRX
Transactions as of
Jun 5, 2024
Transactions value $
$0
Form type
4
Date filed
6/11/2024, 05:50 PM
Previous filing
Aug 18, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OPRX Common Stock Options Exercise $0 +10.1K +45.48% $0.00 32.2K Jun 5, 2024 Direct F1
transaction OPRX Common Stock Award $0 +13.3K +41.29% $0.00 45.5K Jun 7, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OPRX Restricted Stock Units Options Exercise $0 -10.1K -100% $0.00* 0 Jun 5, 2024 Common Stock 10.1K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units convert into common stock on a one-for-one basis.
F2 Grant of restricted stock units representing a contingent right to receive shares of OptimizeRx common stock. The restricted stock units will vest in full on the earlier of the first anniversary of the date of grant or the date of the Company's next annual meeting of shareholders.
F3 On June 7, 2023 the reporting person was granted 10,061 restricted stock units which vested in full on June 5, 2024.

Remarks:

The filing of this Statement shall not be construed as an admission (a) that the person filing this Statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this Statement, or (b) that this Statement is legally required to be filed by such person.